3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
17
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
7
Endometrial Neoplasms
4
Lymphoma, T-Cell, Peripheral
3
Glioblastoma
3
Colorectal Neoplasms
3
Sarcoma
2
Primary Myelofibrosis
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Squamous Cell
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Richter's Transformation
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Pemetrexed
9
Carboplatin
7
pembrolizumab
6
Cisplatin
6
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
ribociclib
3
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled